pp-080 Injection

Indication: Serious infections caused by multidrug-resistant Gram-positive pathogens. Clinical stage: Global multicenter Phase III clinical development following sequential-therapy evaluation; U.S. Phase 2 completed/ China Phase 3 completed. Modality: Small-molecule antibacterial (injectable oxazolidinone). Mechanism / Target: Inhibition of bacterial protein synthesis via binding to the 50S ribosomal subunit, consistent with oxazolidinone pharmacology. Route / form: Injectable formulation, with sequential oral therapy evaluated. Differentiation: Next-generation oxazolidinone engineered to target highly drug-resistant Gram-positive organisms; supported by a national strategic innovation program; QIDP and FDA Fast Track designations underscore its potential to address urgent clinical needs.